No photo of Iracema Leroi

Iracema Leroi, BSc (Hons) LMCC MD FRCPC ABPN MRCPsych

Prof

If you made any changes in Pure these will be visible here soon.

Personal profile

Overview

Current Roles

Professor of Dementia in Aging and Psychiatry, Div of Neuroscience and Experimental Psychiatry Honorary

Honorary Consultant Psychiatrist, Greater Manchester Mental Health Foundation Trust

Dementia Lead, Greater Manchester NIHR Clinical Research Network (GM NIHR CRN)

Associate Director, Manchester NHR Clinical Research Facility

Dementia Clinical Director, DeNDRoN North West
Clinical Lead, Mental Health Domain, Manchester Academic Health Sciences Centre

Faculty member, Parkinson’s Disease Academy (British Geriatric Association)

Previous Roles

Academic:

Clinical Senior Lecturer, Institute of Brain Behaviour and Mental Health, Univ of Manchester

Honorary Lecturer and Honorary Senior Lecturer in Psychiatry, University of Manchester, Dept of Psychiatry

Assistant Professor of Psychiatry, Johns Hopkins University, School of Medicine

Faculty Assistant (Fellow), Johns Hopkins University, School of Medicine

Clinical:

Honorary Consultant Psychiatrist, Manchester Mental Health and Social Care Trust
Consultant Psychiatrist, Manchester Mental Health and Social Care Trust
Consultant Psychiatrist, Lancashire Care NHS Foundation Trust
Staff Psychiatrist, Dalhousie University and Queen Elizabeth II HSC, Halifax, Canada
Resident in Psychiatry (PGY 2 to 5), Dalhousie University, Halifax, Canada
Intern in Psychiatry (PGY1), University of Ottawa, Canada

Journal sub-editorship:

International Journal of Geriatric Psychiatry

Journal associate editorships:
Ageing and Mental Health (Editor, Martin Orrell)
International Psychogeriatrics (Editor, N Lautenschlager)
Current Gerontology and Geriatrics Research
Journal of Geriatrics (Sage Hindawi)

 Invitations as external referee for research

Reviewer (journals)

American Journal of Geriatric Psychiatry, British Journal of Psychiatry, CME Journal of Geriatrics, Drugs and Ageing, European Journal of Neurology, Movement Disorders, Neuropsychopharmacology, International Journal of Geriatric Psychiatry, Journal of Psychopharmacology, Journal of Neuropsychiatry & Clinical Neurosciences, Journal of Geriatric Neurology & Psychiatry, Journal of Alzheimer’s Disease, Journal of Neurology Journal of Medicine and Medical Sciences, J Geriatrics

Reviewer (grant applications)

Alzheimer Society, UK

Alzheimer Research UK

Israel Medical Research Council

National Institute of Health Research, Research for Patient Benefit
Parkinson’s Disease Society Research Division
UK Medical Research Council
German Clinical Trials program

Research interests

Research interests

  • Applications of new technology in dementia
  • Mental health aspects of Parkinson’s disease and neurodegenerative movement disorders, particularly dementia in PD
  • Behavioural & psychological aspects of dementia, particularly apathy in Alzheimer disease
  • Clinical trials in Alzheimer disease and other dementias

Research awards

01/2017:               Novel methodology for analysing gait patterns for the early detection of cognitive decline. Data Science Institute, UMan, £10,000; 3 months pump prime funding.

 01/2015:               SENSE-Cog: Ears, Eyes and Mind – Improving mental health outcomes in people with dementia in the EU; Horizon2020; 6.5million euro

01/2017:               SASHI: South Asia self-harm research capability building. MRC, RCUK, Global Clinical Research Fund (with Pakistan and India). £1.6 million; 48 months (C. Robinson, PI)

06/2015:               InMIND: RCT of an anti-inflammatory agent in MCI. (C Holmes, WP 9 lead) EU funded; 30 million euro

06/2015:               SYMBAD: RCT of mirtazapine v CBZ for BPSD (S Banerjee, PI) NIHR HTA; £1,806,846.20;

04/2015                                MODEM: Eye tracking to detect Alzheimer disease (P. Sawyer, PI: Lancaster U) EPSRC ‘Sensing in Dementia’; £ 960656.65; 42 months.


07/2014: A Psychosocial Intervention to Benefit People with Parkinsons-related Dementia, NIHR Research for Patient Benefit, £342,000 

06/2014: Software Architecture for Self-Management of Mental Health and Dementia (SAMS). EPSRC Working Together Grantreference:             EP/K015826/1, £610,900

05/2014: Is the retina truly a window to the brain? A study of a potential biomarker for dementia, Manchester Interdisciplinary Collaboration on Ageing, Seed Corn Funds, £6000

05/2014: Randomised Controlled Trial of Donepezil in Mild Dementia in Parkinson's Disease (the MUSTARDD-PD Trial) NIHR HTA reference: 08-14-13
NIHR Health Technology Assessment Programme, £2500167 

05/2014: Randomised Controlled Trial of Minocycline in Alzheimer Disease: the MADE Trial, NIHR Efficacy and Mechanism Evaluation programme, £100000 

04/2014: The Manchester High Schools' Dementia Ambassador, Strategic Clinical Network, NHS North (Dementia, Neurology and Mental Health Domain), £20000 

01/2014: A Pilot Project to Develop a Dementia Ambassadors' Programme in Local Secondary Schools in Manchester, International Strategic Support Fund - Wellcome Trust, £6000 

01/2014: Neighbourhoods and Dementia, ESRC, £5000000 

06/2012: Randomised Controlled Trial of Assisted Technology in Dementia: The ATILLA Trial, NIHR Health Technology Assessment Programme, £1800000 

01/2012: Goal Oriented Cognitive Rehabilitation in Dementia: the GREAT Trial, NIHR HTA reference: 11/15/04, NIHR Health Technology Assessment Programme, £22430568          

01/2012: Randomised Controlled Trial of Individualised Cognitive Stimulation in Dementia: The iCST Trial, NIHR HTA reference: 08/116/06, NIHR Health Technology Assessment Programme, £110000 

02/2011: Investigating comorbid cerebrovascular disease in PD, University of Manchester Neuroscience Research Institute: Pump Prime Funding, £50000

01/2009: Randomised Controlled Trial of Lithium Carbonate in Amyotrophic Lateral Sclerosis. The LICALS study, MND Society, £100000

07/2007: Clinical and neural correlates of motivation and reward in PD, Parkinson’s UK Senior Research Fellowship, Parkinson's UK, £238768 

01/2003: RCT of memantine vs placebo in Parkinson’s disease dementia, Lundbeck Ltd, £53000 

01/2001: Neuropsychiatric Aspects of the Spinocerebellar Ataxias, National Association for Research in Schizophrenia & Affective D/O (NARSAD), £50000     

01/2000: Randomized Placebo-Controlled Trial of Donepezil for Cognitive Impairment in Parkinson Disease, Eisai/Pfizer, £121000 

01/2000:  Treatment of cognitive impairment in Parkinson’s disease, Johns Hopkins Neurobehavioral Research Unit Grant, £3500

Teaching

Postgraduate teaching
2013-pres            MSC Cognitive Neuroscience program, Univ Manchester
2013-pres            MSC Dementia Studies, School of Nursing & Midwifery, Univ Manchester
2009-pres            MSC Psychiatry, Univ Manchester (Cluster lead x2)
2006-pres            Parkinson’s Disease Academy Master-class, BGS’s Mov’t D/O subsection
2002-pres            MRCPsych lecturer, Part I and II courses, NW Deanery for Psychiatry

Undergraduate teaching
2012-pres            University of Manchester: Project Options Supervisor
2012-pres            University of Manchester: Medical Student Advisor
2012-pres            University of Manchester: Clinical teaching, psychiatry rotation

Examination duties
2006-pres            Royal College of Physician’s Diploma in Geriatric Medicine 
                            (OSCE type examinations, question setting and validating)

Supervision
 Currently supervises 8 MSc/PhD/DClinPsych students

My collaborations

Memberships of committees and professional bodies

DeNDRoN National Portfolio Management Group
DeNDRoN National Parkinson’s Disease Study Group
British Geriatric Society, Mental Health Rep, exec committee for the Movement Disorder Section
British Geriatric Society, Diploma for Geriatric Medicine examination committee

Clinical guidelines committees:

American Medical Directors Association Parkinson’s disease: Clinical Practice Guidelines (2010)
American Medical Directors Association Parkinson’s disease: Clinical Practice Guidelines (2002)
Consensus Conference: Treatment of Psychiatric Aspects of Huntington’s disease (2001)
Advisory panel member (deputy mental health representative) National Institute of Health and Clinical Excellence, Parkinson’s Disease Clinical Guidelines (2005)

Qualifications

Bachelor of Science (BSc; Zoology), University of British Columbia, Canada
Doctor of Medicine (MD, Canada), University of British Columbia, Canada
Licentiate of the Medical Council of Canada (LMCC)
Fellow of the Royal College of Physicians & Surgeons, Canada (FRCPC)
Board Certified American Board of Psychiatry and Neurology (ABPN)
Member of the Royal College of Psychiatrists (MRCPsych)
Doctor of Medicine (MD, UK), University of Manchester

Good Clinical Practice (GCP) in research certification, updated 2012
Mental Health Act Section 12 approved

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Research Beacons, Institutes and Platforms

  • Dementia@Manchester
  • Manchester Institute for Collaborative Research on Ageing

Keywords

  • Alzheimer disease
  • Behaviour Change
  • Dementia
  • Mental Health
  • cognitive impairment

Fingerprint

Dive into the research topics where Iracema Leroi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or